ABSTRACT
INTRODUCTION
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is a ubiquitous toxin, and a prototypical representative of a series of chemicals which effect toxicity through a common mechanism, binding to the Aryl Hydrocarbon Receptor (AhR) [1, 2] . Mouse genetic studies demonstrated that dioxin toxicity is mediated through the AhR locus [2] , and the subsequent cloning of the AhR [3, 4] characterised the AhR as a transcription factor. The creation of AhR knockout mice enabled a confirmation that AhR was required for dioxin toxicity [5] [6] [7] [8] .
For a variety of persistent ligands, the affinity of the AhR for the ligand is directly related to toxicity endpoints [1, 2] . Hence determining the affinity of ligands for AhR gives key information for evaluating toxicity. The AhR ligand-binding assay is exquisitely sensitive to minor changes in methodology e.g. [9, 10] , and this leads to large differences (greater than 100-fold) in measured affinity of AhR for TCDD between different laboratories, e.g. [1, [10] [11] [12] . Therefore, measured affinity constants for AhR ligands are not necesarily directly comparable between laboratories.
There are marked species differences in the toxicity of TCDD [2] , and it is important to determine if these differences are due to binding to the AhR, and if they are common to other ligands of the AhR. The relative affinity of the human and mouse AhR for TCDD is known [13] [14] [15] , but the affinity of the human AhR for other ligands has not been determined [12, 16] ; this knowledge deficit arises partly because of difficulties in obtaining fresh human tissue, but also because analysis of AhR in human tissues is affected by the lability and low levels of the human AhR [16, 17] . Consequently, it is problematic to compare the affinity of human AhR for ligands with AhR affinity data for toxicologically relevant model species, if this latter data is generated in a different laboratory.
Hence a recombinant expression system would enable reliable comparison between AhR preparations in the same laboratory under controlled conditions. Whilst reticulocyte lysates are capable of producing AhR with ligand-binding functionality [3] , the amount of AhR produced in this system is small and quantitative assays require considerable amounts of lysate [18] , effectively precluding this method for comparison of multiple ligands in multiple species. Mammalian cells are also capable of producing small amounts of functional AhR, but Ramadoss et al. [19] found limitations in saturation binding analysis in vitro with this system, and were unable tera frugiperda) cells is a system capable of producing high levels of recombinant protein, that has been exploited for a variety of transcription factors. Whilst human AhR has been expressed in this system [20] , there was no quantitative measurement of the amount or affinity of the ligand-binding AhR in this system. This is a prerequisite for studies on ligand-binding, and for validating that the AhR is correctly folded. Thus there is a pressing need for a recombinant expression system that can yield high levels of functional AhR, and that can be used in a saturation binding analysis to give quantitative measures of ligand affinity with AhRs from different species.
We have investigated the use of baculovirus for recombinant expression of the AhR. We characterise the biochemical parameters required for functional expression of the AhR in this system, quantify the amount and ligand-binding functionality of expressed AhR, and show that it faithfully reflects the native receptor. The high-level expression of functional AhR has numerous applications, and as an example, we use the recombinant rat and human AhR to demonstrate and quantify binding affinity for a number of ligands. TCDD and congeners (PCDD, 1 
MATERIALS AND METHODS

Materials
Sub-cloning of rat and human AhR cDNAs
A rat (Charles River Wistar-CRL:WI) was killed, and liver was homogenised in TRIzol Reagent (Invitrogen). Total RNA was extracted from liver according to the manufacturer's manual.
mRNA was purified by Oligotex mRNA Spin-column (Qiagen) according to the manufacturer's manual. RT-PCR (Prostar Ultra HF RT-PCR kit (Stratagene)) was used to clone rat AhR and its ligand-binding domain sequences according to the manufacturer's instructions. The PCR primers were designed based on the known Sprague-Dawley rat AhR cDNA sequence (Table 1) , and the first nine amino acids (leader sequence) were deleted. Rat AhR cDNA was divided into two pieces (primers rA5 and rALB3; rABam3 and rLBDreverse), amplified separately and ligated together at the BamHI site. Rat AhR ligand-binding domain was amplified by primers rALB5 (forward), which contains a novel Sal I site, and rALB3 (reverse) containing the Hind III site and six-histidine tag. All PCR products were subcloned into either pGEMT-Easy (Promega) or pPCR Script (Stratagene) plasmid, and analysed by double-strand DNA sequencing. The AhR cDNA clones were then inserted into plasmid pFastBac1 between the SalI and HindIII sites.
Human AHR cDNA, and its ligand-binding domain, were amplified by PCR from plasmid pSporthAhr2 (Susan Moran, Mcardle Lab. for Cancer Research, University of Wisconsin-Madsion Medical School); the primers are listed in Table 1 . The human AHR-His and hAHR-LBDHis fragments were then subcloned into Sal I and Hind III sites of plasmid pFastBac1.
The plasmid pFastBac1.Gus (Invitrogen) was used as a positive control to prepare recombinant -glucuronidase (GUS) baculovirus, using the same method as described above. Baculovirus expressing human p23 was described previously [21] , and was a kind gift from David O. Toft (Mayo Graduate School, Rochester, MN 55905, USA).
Site-directed mutagenesis
Quick-change mutagenesis kit (Stratagene) was used to generate the V381A mutant of the hAhR LBD construct, according to the manufacturer's instructions. The amino acid at 381 is variant between rat and human (V/A), and mutation of this amino acid is known to confer high affinity binding [13, 14] . The mutant primer is shown in Table 1 . The plasmid pFastBac1/ hAhR-LBD was used as the template. The mutation was confirmed by double-stranded DNA sequencing.
Expression of recombinant AhRs
The Bac-to-Bac (Invitrogen) system was used to express recombinant AhRs in insect cells.
Briefly, the plasmids pFastBac1/hAhR-His, pFastBac1/hAhR-LBD-His, pFastBac1/V381A- of the supernatant was removed and radioactivity was measured in a scintillation counter. Specific binding was defined as the difference of radioactivity between without (total binding) and with competitor TCAOB (non-specific binding). For recombinant rat AhR protein, either 0.25mg or 0.5mg/ml cytosol protein was used for binding assay, and supplemented with BSA to a final protein concentration of 5mg/ml; 1mg/ml recombinant human AhR with 4mg/ml BSA was used for assay unless otherwise stated. For competition assay, a serial dilution of competitor was incubated with 0.5nM [ 3 H]-TCDD (except where otherwise stated), and the specific binding was determined as described above. Specific binding or K i was determined by using nonlinear regression, using Graphpad 4/5, fitting a saturation binding isotherm, or one-site competitive binding equation, to the experimental data. K i was derived from the IC 50 using the ChengPrusoff equation, as implemented in Graphpad.
Hydroxylapatite assay
200l sample was treated with charcoal as described above; the supernatant was transferred into a fresh tube, then 200l 50% hydroxyapatite (HAP) was added. After incubation on ice for 30 minutes, the HAP resin was spun down at 25000g for 1 minute at 4C. The pellet was washed twice with 1ml MDEG buffer containing 0.1% Tween 20, and then the protein was eluted into 0.5ml ethanol. The supernatant was assayed for radioactivity by liquid scintillation counting.
Analysis of saturation-binding data was as described for the charcoal assay above.
Western blotting
Protein was run on polyacrylamide gel electrophoresis (PAGE) (either SDS-PAGE, or pre-cast gels (Invitrogen) using lithium dodecyl sulphate), and transferred to a blotting membrane. Signal was detected using Enhanced Chemiluminescence (ECL; GE Healthcare) and exposure to a -affinity chromatography. The purified protein was used to immunise rabbits, and antiserum harvested when the bleeds were capable of detecting <1ng of antigen.
Statistical analysis
Data is presented as mean and standard deviation, except where otherwise noted. Statistical analysis used t-test where appropriate. For calculation of confidence intervals from saturation, and competition ligand-binding, Graphpad 5 was used for calculation of 95% confidence limits subsequent to non-linear curve-fitting.
RESULTS
Generation of baculovirus constructs and expression of protein
The AhR cDNA was cloned from the liver of a CRL:WI rat, and the sequence of the constructs (Accession number AJ821851) was confirmed by double-stranded sequencing to be identical for that of the Sprague-Dawley rat (AAA56897). The human and rat cDNAs were cloned into recombinant baculovirus, used to infect Sf9 insect cells, and the presence of AhR determined using western blotting (Fig. 1A) . Cytosol from uninfected cells showed no noticeable cross-reactivity with the antibody, and cells infected with a virus expressing -glucuronidase also failed to show any cross-reactivity, demonstrating that viral infection did not cause any cross-reacting proteins. Virus expressing rat and human AhR both gave rise to strong immunoreactive bands in cytosol, with the human AhR migrating at a slightly higher apparent molecular mass than the rat AhR, consistent with previous reports [22] . This shows that the AhR protein was specifically expressed and detected in Sf9 cells. The time course of expression of cytosolic AhR protein was examined (Fig. 1B) ; AhR protein was maximally induced at 48 hours after infection, and this time point was used for further studies. Comparison of the amount of AhR protein in total cell lysates versus cytosol (Fig. 1C) showed that both the human and rat AhR were more abundant in total cell protein, compared to cytosol. This effect was more obvious for the human AhR, than for the rat AhR. The full-length and Ligand-Binding Domain (LBD) constructs were then expressed at an equal Multiplicity of Infection with virus (MOI), to determine if there was adequate expression of the recombinant proteins in cytosol (Fig. 1D) . While the expression of the full-length human and rat AhR proteins was adequate, the expression of the LBD constructs was less than that seen for the full-length constructs. The rat LBD was present in cytosol at acceptable levels, but the human AhR LBD and the LBD-Val381Ala mutant were present at too low a level for comparison with the rat LBD or full-length constructs (Fig. 1D) . Thus the Sf9 expression system yielded high levels of expression of both rat and human full-length AhR proteins in cytosolic extracts.
Ligand-binding assay
Given that the expression system yielded cytosolic full-length human and rat AhR protein, it was necessary to test whether the protein was capable of specifically binding a ligand; the prototypical ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) was used, with rat liver cytosol as a positive control reagent. Fig. 2A , B shows that uninfected Sf9 cytosol (a negative control)
showed no specific binding to tritiated TCDD, but that rat liver cytosol bound TCDD. Cytosol from Sf9 cells infected with either rat AhR (A) or human AhR (B) showed specific binding to TCDD, demonstrating that the recombinant AhR protein is capable of binding ligand. The binding assay was robust to the use of 2,3,7,8-tetrachlorodibenzofuran (TCDF) or tetrachloroazoxybenzene (TCAOB) as a competitor to determine specific binding (unpublished data), and the amount of specific binding was not significantly different when using a protocol with charcoal, or charcoal followed by an additional hydroxyapatite step (Fig. 2C) . The assay showed specific binding to TCDD with rat liver cytosol (Fig. 2D) , with saturation binding analysis for rat cytosol yielding an apparent K d for TCDD of 1.0 ± 0.45 nMolar (mean ± Standard deviation, n=6), and a maximal binding capacity (B max ) of 52 fmol/mg, within the range of previous estimates [1, 10, 12] .
Optimisation of recombinant expression for ligand-binding competent AhR
Protein concentration is a key variable for TCDD binding assays, since TCDD solubility is critically dependent upon protein concentration (DRB, unpublished data; [9, 10] (Fig. 3C) . Finally, performing the ligand-binding assay in the presence of a high concentration of TCDD also had no effect on the inhibition of rat AhR by Sf9 cytosol, confirming that the effect is not caused by a surfeit of AhR binding sites. The known dependence of AhR folding on protein interactions (e.g. [23, 24] ) suggested that proteins in the Sf9 cytosol may be causing the AhR to adopt an improperly folded conformation; to test this, the Sf9 cytosol was heat treated, whereupon it then failed to inhibit the binding of rat AhR to TCDD (Fig. 3D) . Reticulocyte lysates are known to be able to support the folding of AhR into a ligand-binding capable form (e.g. [25] [14]), and so reticulocyte lysate protein was used to determine if the inhibitory effect of Sf9 protein was specific to
Sf9 cells, or a general phenomenon of cell lysates. Fig. 3E shows that the specific binding of rat AhR to TCDD was unaffected by reticulocyte lysate protein over a range of 0-5 mg/ml, thereby
showing that the effect of Sf9 cytosol in inhibiting the binding of TCDD to recombinant rat AhR is specific to the Sf9 cytosol, as opposed to reticulocyte lysate or BSA solution.
It has previously been shown that p23 is an essential chaperone for correct folding of the glucocorticoid receptor [21] , and it is known that p23 associates with the AhR. In order to determine if p23 could enhance the folding of AhR in Sf9 cells, rat AhR was co-expressed with human p23. Fig. 4A shows that baculovirus expression of p23 yields sufficient soluble p23 for visual detection in a coomassie-stained gel, and immunodetection confirmed that the induced band was indeed p23, and neither Sf9 cells, nor AhR-encoding baculovirus caused any cross-reactivity (Fig. 4B) . AhR was co-expressed with p23 protein, and there was no obvious effect on the amount of AhR protein that was present in cytosolic extracts in the presence and absence of coexpression of p23 (Fig. 4C) ; this was true when the rat AhR was expressed at low levels (MOI of 0.1) and at higher levels of expression (MOI=1). The functionality of the expressed rat AhR protein was examined by ligand-binding assay, and there was no significant difference in the amount of specific binding of TCDD between cytosols containing rat AhR with and without p23 protein (Fig. 4D) . Thus the expression of p23 had no effect on the yield of cytosolic protein, nor the functionality of expressed AhR under these conditions in Sf9 cells.
Determination of affinity of rat and human AhR for TCDD
In view of the consistent cytosolic expression of rat and human AhR, and qualitative determination of ligand-binding ability, saturation binding analysis was undertaken to quantitate the amount and affinity of binding. When cytosol containing recombinant rat AhR was produced at an MOI of 0.1, the resulting AhR showed saturable binding to TCDD (Fig. 5A) , with a K d of 1.34 ± 0.32 nM (n=6 independent determinations). This value was not significantly different from the values we obtained for the AhR in rat liver cytosol (1.0 ± 0.45nM, n=6, Fig. 2D ), dem-onstrating that the baculovirus expression system yields faithful expression of functional rat AhR. The B max was 1.5±0.37 pmol/ mg cytosolic protein, ~20-fold higher than in rat liver cytosol (Fig. 2D) . Expression of rat AhR with higher MOI yielded slightly higher amounts of cytosolic AhR protein (Fig. 5B ), but no increase in the amount of specific binding to TCDD (Fig.   5C ). In order to confirm that the recombinant expression system could functionally express AhR from different organisms, the affinity of TCDD for human AhR under optimised conditions was determined, yielding a K d of 2.77± 0.94 nM (n=6), with a B max of 0.46±0.12 pmol/mg cytosolic protein (Fig. 5D ). Although we did not determine the affinity of native human liver AhR, this data is consistent with previous reports in showing that the human AhR has a significantly reduced affinity for TCDD compared to rat [13] 
Determination of ligand affinity by competitive binding assay
In order to determine if the expressed AhR could be used to determine the affinity of other ligands, the rat AhR was used in a competition binding assay for a number of congeners of TCDD (Table 2 ). The competition assays showed good fit to a one-site competitive binding assay equation, and were robust to replication (data not shown). The rat AhR yielded a K i for TCDD which was not significantly different from the Kd determined from rat liver, or recombinant rat AhR (Fig. 5A) , demonstrating that the competitive binding assay with recombinant AhR is robust.
Comparison of the ability of various congeners to bind to rat AhR showed that TCDF and PCDD showed a similar affinity as TCDD, but that PCDF was a ~three-fold less potent ligand than PCDD, and PCB126 was ~50-fold less potent than TCDD. For the human AhR, TCDD and PCDF were ~two-fold less potent than TCDF and PCDD, and PCB126 was ~40-fold less potent as a ligand than TCDD ( Table 2 ). The K i values for the human AhR consistently showed the same rank order of potency as in the rat; however, as with the K d values, the human AhR showed a lower affinity for ligands when compared with the rat. Thus these data demonstrate that the recombinant AhR can be used for the determination of ligands in a competitive ligand-binding assay.
DISCUSSION
Recombinant expression of ligand-binding competent AhR would have significant advantages for determining the ligand-binding affinity of AhR from a variety of organisms, but expression of AhR is problematic. Bacterial expression of AhR yields insoluble protein [18] , and even in insect cells, the majority of the AhR protein produced was in an insoluble 10 000 g pellet (MQF, TJ, unpublished data, [20] ). However, the full-length AhR proteins produced cytosolic AhR in insect cells, and these levels were readily detectable (Fig. 1C, D) . Thus high levels of cytosolic expression of full-length AhR proteins was achieved, and it was necessary to determine whether these proteins were able to bind ligand.
Surprisingly, the specific binding of TCDD to infected Sf9 cytosols was dependent upon the concentration of Sf9 cytosol in the binding reaction (data not shown, Fig. 3A) . The ligand-binding assay for AhR is a complex assay, which depends upon maintaining TCDD in solution by low-affinity binding of TCDD to protein or other macromolecules, and so can be prone to artefactually induced interpretation arising from distinct constituents between Sf9 cytosol and other reagents tested. We firstly demonstrated that this was not due to an artefact, such as the presence of small molecular weight ligands in Sf9 cytosol (Fig. 3C) , or the failure of the cold competitor to saturate specific binding (Fig. 3B, C) . The fact that heat treatment of Sf9 cytosol abolishes the inhibition of AhR binding (Fig. 3D) suggests that the inhibition is caused by proteins, consistent with previous findings that protein chaperones are essential for AhR folding (e.g. [23, [26] [27] [28] ). We specifically tested whether p23 could enhance AhR folding; p23 is known to enhance folding of the baculovirus-expressed glucocorticoid receptor in Sf9 cells, and is required for baculovirus-expressed human AhR and ARNT to bind to DNA response elements [29] .
However, p23 alone had no effect on AhR solubility or ligand-binding (Fig. 4) ; this is in contrast to the requirement for p23 with glucocorticoid receptor in Sf9 cells [21] . Thus it remains unclear exactly what proteins are involved in the proper folding of AhR, and this is a key issue for obtaining high yields of AhR for structural studies.
Recombinant cytosolic AhR was tested for ligand-binding functionality, and reproducibly produced saturable ligand-binding to TCDD (Fig. 5A) . The K d for the recombinant expressed AhR was not significantly different from that determined with rat liver cytosols using the same experimental protocol (Fig. 2, Fig. 5 ), and these are in turn directly comparable with previous determinations [12] [10] [30] . We did not have access to fresh human liver to undertake an analysis of native human AhR ligand affinity, but the affinity of the recombinant human AhR was comparable to literature values [31] [16] [32] . This demonstrates that expression of the AhR using baculovirus yields protein with similar ligand-binding functionality to the native form, and validates the use of recombinant AhR. The relatively high levels of expression of functional recombinant AhR described in this report is an important advance, as this is the first system that generates sufficient functional receptor for e.g. comprehensive ligand-binding studies or protein purification/ structural analyses.
Several invertebrate species have been characterised to have non-ligand-binding AhR genes [33] [34] [35] , and so it is likely that Spodoptera cells also lack a ligand-binding AhR. In agreement with this, we were unable to detect any reproducible or significant specific binding of The human and rat AhR showed robust and saturable ligand-binding affinity for TCDD (Fig. 5) , consistent with previous data [12] [13] [14] , and hence can be used for further ligand-binding analysis.
We undertook a comparison of the ability of rat AhR to bind TCDD, and the value in competitive binding assay was not significantly different from that obtained in an equilibrium binding analysis ( Table 2 ). The rat AhR showed specific binding to a range of dioxins and furans, in agreement with prior estimates [1, 2] . The human AHR bound specific ligands in the same rank order of affinity as the rat, but with lower affinity than the rat AhR (Table 2) Competitive binding assays were carried out using rat or human AhR, as described in materials and methods. Each experiment was carried out in triplicate, and results are the mean, with 95% confidence limits shown in square brackets.
TABLES
